CDEK
← All drugs Report issue

clazakizumab

mAbexperimental

Clazakizumab, an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect. — Wikipedia

Clinical trial activity

22 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
20
Phase 3
3
Phase 4
0

Earliest trial started Sep 1, 2008 (NCT00866970)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ald518
  • ald518
  • bms-945429
  • bms-945429
  • bms-945429
  • clazakizumab
  • clazakizumab
  • clazakizumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05727384Phase 2Aug 1, 2023CSL Behring, University of Pittsburgh
NCT05485961Phase 2/Phase 3 (Phase 3)Sep 30, 2022CSL Behring
NCT04659772Phase 2Dec 31, 2020Mayo Clinic, New York University
NCT04494724Phase 2Jul 13, 2020Methodist Cancer Center, Houston, Texas
NCT04381052Phase 2May 31, 2020Columbia University, New York University, Vitaeris
NCT04363502Phase 2May 7, 2020—
NCT04348500Phase 2Apr 21, 2020Cedars-Sinai Medical Center
NCT04351724Phase 2/Phase 3 (Phase 3)Apr 16, 2020Hospital Hietzing, Kaiser Franz Josef Hospital, Medical University Innsbruck, Medical University of Vienna, Otto Wagner Hospital, SMZ-Ost Donauspital, Wilhelminenspital der Stadt Wien
NCT04343989Phase 2Mar 31, 2020New York University
NCT04129931Phase 2Nov 30, 2019National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill
NCT03744910Phase 3Jun 30, 2019ICON, Vitaeris
NCT03380377Phase 1/Phase 2 (Phase 2)Feb 21, 2018Cedars-Sinai Medical Center
NCT03380962Phase 1/Phase 2 (Phase 2)Feb 21, 2018Cedars-Sinai Medical Center
NCT03444103Phase 2Jan 16, 2018Humboldt University, Medical University of Vienna, University of Alberta, Vitaeris
NCT02015520Phase 2Jan 1, 2014Alder Biopharmaceuticals, Bristol-Myers Squibb
NCT01545050Phase 2Jun 1, 2012Alder Biopharmaceuticals, Bristol-Myers Squibb
NCT01530256Phase 1/Phase 2 (Phase 2)Mar 1, 2012Alder Biopharmaceuticals
NCT01490450Phase 2Dec 1, 2011Alder Biopharmaceuticals, Bristol-Myers Squibb
NCT01403064Phase 2Jul 1, 2011Alder Biopharmaceuticals
NCT01373151Phase 2Jun 1, 2011Alder Biopharmaceuticals, Bristol-Myers Squibb
Showing 20 of 22 trials
Page 1 / 2

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alder BiopharmaceuticalsFor profit8812008
Bristol-Myers SquibbFor profit4012011
Cedars-Sinai Medical CenterAcademic/Hospital3312018
New York UniversityAcademic/Hospital3212020
VitaerisFor profit3122018
CSL BehringFor profit2122022
Medical University of ViennaAcademic/Hospital2222018
Columbia UniversityAcademic/Hospital1112020
Hospital HietzingAcademic/Hospital1012020
Humboldt UniversityAcademic/Hospital1012018
ICONFor profit1012019
Kaiser Franz Josef HospitalAcademic/Hospital1012020
Mayo ClinicAcademic/Hospital1012020
Medical University InnsbruckAcademic/Hospital1012020
Methodist Cancer Center, Houston, TexasAcademic/Hospital1112020
National Heart, Lung, and Blood Institute (NHLBI)Government1012019
Otto Wagner HospitalAcademic/Hospital1012020
SMZ-Ost DonauspitalAcademic/Hospital1012020
University of AlbertaAcademic/Hospital1012018
University of North Carolina at Chapel HillAcademic/Hospital1112019
22 organizations
Page 1 / 2